Kewajiban jangka dawa marang ekuitas Sight Sciences Inc (SGHT)

Sight Sciences, Inc. (SGHT) implements minimally invasive methods to combat glaucoma and dry eye by restoring natural fluid drainage. This chart illustrates the asset's price action, where the indicator stands at 0.61. The business relies on the production of affordable, high-margin OMNI plastic microcatheters, pursuing profitability through the expansion of US insurance reimbursements and physician training.

This indicator measures the proportion of liabilities with a maturity exceeding one year relative to equity, determining the business's financial resilience to external crises. Analyzing the long-term debt-to-net assets ratio allows for an assessment of leverage efficiency, which is critical for Sight Sciences (SGHT) when scaling sales of glaucoma treatment systems and managing legal expenses.